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ABSTRACT 
 
Familial idiopathic basal ganglia calcification (FIBGC) or Fahr's syndrome is a rare disorder with 
various clinical presentations which can mimic - in particular - psychiatric illness. The following case 
is characterized by the typical basal ganglia calcifications and presentation of neuropsychiatric 
symptoms indicating the first clinical presentation in the absence of a neurological deficit. As 
previously reported, the extent of calcification did not predict neurological impairment, however, 
predicted severe psychosis. 
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1. BACKGROUND 
 
FIBGC or Fahr's disease or syndrome is a rare, 
neurological disorder characterized by abnormal 
calcified deposits in the basal ganglia and 
cerebral cortex, and typically affects individuals 
in the 3rd and 4th decades of their lives [1]. 
 
Etiologically, this syndrome has been most 
commonly associated with endocrine disorders, 
mitochondrial myopathies, dermatological 
abnormalities, and infectious diseases. The 
understanding of the molecular genetics of this 
disorder still remains limited. 
 
Clinically, a range of symptoms including 
neurological symptoms such as extrapyramidal 
symptoms, parkinsonism, chorea, or tremors, to 
neuropsychiatric deficits of concentration and 
memory have been described. 
 
2. CASE REPORT 
 
Mr. A. is a 57-year-old male patient with pituitary 
germinoma, s/p resection and radiation therapy 
resulting in pituitary insufficiency requiring 
desmopressin substitution and no previous 
psychiatric history. The patient presented with a 
loss of consciousness and myoclonic seizures, 
followed by an altered mental state including 
hallucinations and delusions, as well as agitation 
and aggressive behavior. Police and ambulance 
had to be notified and the patient required 
sedation for the transfer to the emergency room. 
The initial presentation of symptoms occurred 
two months before, the family reported episodes 
of unresponsiveness, disorientation, inability to 
use the computer, and play video games. 
 
In the emergency room, the patient continued to 
report hallucinations like grimacing faces, angels 
and the Holy Ghost, as well as delusions like his 
marriage was not going well, being wary his wife 
could be wearing a mask. Furthermore, he was 
disoriented, anxious and psychomotor retarded. 
 
Initial laboratory findings revealed a discrete 
hyponatremia (125 mmol/l) from over-
administration of desmopressin and a mildly 
increased creatinine kinase (320 U/l). The 
complete blood count and electrolytes were 
within normal limits, including calcium, 
phosphorus, and magnesium. Liver function tests 
including the alkaline phosphatase were normal. 
Endocrinologically, the parathormon level was 
within normal limits. The cerebral spinal fluid 
exam yielded no abnormalities. 
A computed tomography scan of the brain 
revealed profound calcifications of the basal 
ganglia bilaterally (Fig. 1.). An MRI confirmed the 
post-ischemic changes in the right superior 
parietal lobes and obstruction of the right carotid 
artery and collateralization of the middle cerebral 
artery. An encephalographic study revealed 
discrete general changes and a mild focus in               
the right temporal lobe. Neurologically, a 
documented right amaurosis and discrete post-
ischemic hemiparesis of the left lower extremity 
were present, and no movement disorder 
discovered.  
 
The patient was admitted for further 
management and work-up. The hyponatremia 
was corrected and over the following days and 
the neuropsychiatric symptoms remitted. The 
patient was able to return home and follow-up 
was arranged. 
 
Molecular genetic testing was not deemed 
necessary, as no family history existed. 
 
3. REVIEW OF THE LITERATURE 
 
The diagnostic criteria of FIBGC or Fahr's 
syndrome include 1- bilateral calcification of the 
basal ganglia, 2- progressive neurologic 
dysfunction, 3- the absence of biochemical 
abnormalities, an infectious, traumatic or toxic 
cause, and 4- a significant family history [1]. 
 
The presentation of Fahr’s syndrome varies and 
the diagnosis remains challenging. In adults, 
both loss of consciousness and seizures have 
been reported in patients with hypothyroid 
hypocalcaemia [2]. Tetany can occur, which is 
difficult to distinguish from occasional          
myoclonus caused by an epileptic disorder. 
Further neurologic manifestations include 
spasticity, gait disorder, speech impairment, 
dementia, parkinsonism, chorea, tremors, 
dystonia, myoclonus, and coma, paroxysmal 
choreoathetosis, even of the                    
dystonic-choreoathetotic type, as well as 
papilledema due to intracranial hypertension, 
CSF-pleocytosis, [1]. 
 
The prevalence of the neurological 
symptomatology in Fahr's syndrome ranges from 
one third to one half of patients [3,4]. Generally, 
the location and extent of lesions have an effect 
on the manifestation; in particular in patients  
with dementia or patients with extrapyramidal 
symptoms, more extensive lesions cause more 
severe symptomatology [5]. 
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Fig. 1. Cranial computed tomography. Profound calcifications of the basal ganglia bilaterally 
as typically seen in FIBGC or Fahr’s syndrome
On the genetic basis, FIBGC or Fahr’s disease is 
most commonly transmitted as an autosomal 
dominant trait, however, also transmitted as an 
autosomal recessive trait, or occurs sporadically. 
A locus at 14q (IBGC1) is commonly involved, a 
second locus on chromosome 8, and a third on 
chromosome 2. On the molecular level, on 
chromosome 8, a loss of function-mutation in the 
gene encoding type III sodium dependent 
phosphate transporter 2 (SLC20A2) has been 
thought to form the genetic basis for the 
pathophysiology of this disease. In instances, in 
which no identifiable mutation or deletion in 
SLC20A2 can be found, the platelet-derived 
growth factor receptor-subunit beta (PDGFRB) 
might be another sequence worthwhile 
evaluating [1]. In addition, in patients with 
mutations on the platelet-derived growth factor-
subunit beta (PDGFB) gene, white matter lesions 
have been documented in various areas of the 
brain [6]. Another gene implicated in FIBGC, 
encodes the xenotropic and polytropic retrovirus 
receptor 1 (XPR1), a receptor with phosphate 
export function [7]. 
 
The neuropsychiatric symptoms range from mild 
cognitive impairment to changes in personality 
and behavior, to dementia and psychosis [1]. In 
rare presentations, frontotemporal dementia, 
neurofibrillary tangles and calcification of the 
Fahr's type have been described, however, 
neither extra-pyramidal symptoms nor metabolic 
disorder occurred. In unusual presentations              
of pre-senile dementia, imaging revealed 
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calcareous depositions of Fahr's type, as well as 
Alzheimer's as well as frontotemporal dementia 
were ruled out. In addition, severe compromised 
attention and memory were reported in a patient 
FIBGC and with intact basic and higher motor 
function. In all of these FIBGC patients, 
neurological symptoms were not present [8]. 
 
Fahr’s syndrome may also present with frontal 
lobe symptomatology; initially, uncontrollable 
bursts of laughter and crying were noted and 
later dysarthria, as well as progressive changes 
in personality and behavior [9]. In another patient 
with disturbed selective attention and cognitive 
flexibility, verbal perseverations, and declarative 
memory deficits, a reduced glucose uptake in the 
Positon Emission Tomography (PET) scan was 
not only confined to the putamen and globus 
pallidus, but extended to the bilateral temporal 
and parietal cortices, corresponding to the 
neuropsychological deficits observed. Functional 
imaging revealed that the changes preceded 
cerebral atrophy in Fahr's syndrome and 
reflected deficits in functional circuits involving 
the basal ganglia and the frontal, parietal and 
temporal lobes [10]. 
 
The current understanding indicates that              
the extent of calcification does not predict 
neurological impairment, however, predicts 
neuropsychiatric disorders. 
 
Diagnostically, recommended imaging includes 
cranial CT or MRI and plain radiography of the 
skull. Further investigations of interest include 
blood and urine testing for hematologic and 
biochemical indices. 
 
Calcification of the basal ganglia is an incidental 
finding in about 0.3%-1.5% of brain CT scans, 
especially in elderly individuals. Microscopic 
calcifications have been observed in the globus 
pallidus and dentate nucleus in up to 70% of 
autopsy series. However, calcifications confined 
to this area usually do not cause clinical 
symptomatology [1]. 
 
Endocrine disorders, in particular parathyroid 
disturbances such as hypo- and 
hyperparathyroidism have been most commonly 
associated with Fahr's syndrome and vitamin D, 
crucial for the calcium metabolism and its 
homeostasis, has significant implications [1]. 
 
To date, no curative approach exists for Fahr's 
syndrome; as a consequence, management 
strategies mainly focus on symptomatic relief and 
elimination of causative factors. Limited evidence 
suggests that early diagnosis and management 
can reverse the calcification process leading to 
complete recovery of mental functions. Various 
treatments have been administered to Fahr's 
patients in an attempt to achieve stabilization  
and remission. These approaches base on 
pathophysiological theories resulting in the 
proposal of small scale clinical experiences. 
 
4. CONCLUSION 
 
In summary, this case of FIBGC  or Fahr's 
syndrome initially presenting with psychosis in 
the absence of neurological deficits, in particular 
movement disorder, and dementia, which, to 
date, has not yet been reported in the               
literature and adds to the evidence that the 
typical calcification predicts neuropsychiatric 
symptomatology in contrast to neurological 
deficits. Since other etiologies contributing to the 
presentation have been ruled out and the typical 
calcifications were present, this case illustrates 
the necessity for a heightened awareness of 
potential Fahr's syndrome and the obligatory 
requirement of cranial imaging in order to confirm 
the diagnosis. 
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